TrialThe Journal of infectious diseases2025

Phase 3 Study Assessing Lot-to-Lot Consistency of Respiratory Syncytial Virus Prefusion Protein F3 Vaccine and Its Immune Response, Safety, and Reactogenicity When Co-administered With Quadrivalent Influenza Vaccine.

Nnenna Chime et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.